US · Healthcare · Biotechnology
EPS came in at -0.69 against a street estimate of -0.71 — a beat of 2.8%.
Analysts rate Denali Therapeutics Inc a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $34.31.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.21% |
| Baillie Gifford & Co Limited. | 7.60% |
| T. Rowe Price Investment Management,Inc. | 5.37% |
| Temasek Holdings Ltd. | 4.42% |
| State Street Corp | 3.95% |
| Vanguard Capital Management, LLC | 3.87% |
| Vanguard Portfolio Management, LLC | 3.86% |
| FMR Inc | 2.88% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 | 2026-07-28 |
| Material agreement · Q2 2026 | 2026-06-18 |
| Shareholder vote results · Q2 2026 | 2026-06-04 |
| Reg FD disclosure · Q2 2026 | 2026-05-22 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q4 2025 | 2026-04-21 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Denali Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.